Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1776-1783

  Alexander, Frances ^a   Matheson, Mary ^a   Fry, Norman K ^a   Labram, Briony ^a   Gorringe, Andrew R ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; FIM2 PROTEIN; FIM3 PROTEIN; IMMUNOGLOBULIN G; PERTUSSIS TOXIN; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN PURIFICATION; ARTICLE; BACTERIAL STRAIN; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; COUGHING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MOUSE; NONHUMAN; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIMBRIAE PROTEINS; HUMANS; IMMUNOGLOBULIN G; INFANT; PERTUSSIS VACCINE; VACCINES, ACELLULAR; VIRULENCE FACTORS, BORDETELLA;

EID: 84868246802     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00355-12     Document Type: Article

References (32)

1. Baughman AL, et al. 2004. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin. Diagn. Lab. Immunol. 11:1045-1053. (Pubitemid 39540842)
2. Chen Q, Decker KB, Boucher PE, Hinton D, Stibitz S. 2010. Novel architectural features of Bordetella pertussis fimbrial subunit promoters and their activation by the global virulence regulator BvgA. Mol. Microbiol. 77:1326-1340.
3. Cherry JD, Gornbein J, Heininger U, Stehr K. 1998. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906. (Pubitemid 28473933)
4. Cherry JD, et al. 2010. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin. Vaccine Immunol. 17:741-747.
5. Geuijen CA, et al. 1998. Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis. Infect. Immun. 66:2256-2263. (Pubitemid 28194128)
6. Geuijen CA, Willems RJ, Mooi FR. 1996. The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars. Infect. Immun. 64:2657-2665. (Pubitemid 26226830)
7. Gorringe AR, Ashworth LAE, Irons LI, Robinson A. 1985. Effect of monoclonal antibodies on the adherence of Bordetella pertussis to Vero cells. FEMS Microbiol. Lett. 26:5-9. (Pubitemid 15102389)
8. Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM. 2005. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J. Clin. Microbiol. 43:2856-2865. (Pubitemid 40827964)
9. Hallander HO, et al. 2009. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection. APMIS 117:660-671.
10. He Q, Mertsola J. 2008. Factors contributing to pertussis resurgence. Future Microbiol. 3:329-339. (Pubitemid 352003143)
11. Heikkinen E, et al. 2008. Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol. 8:162.
12. Imaizumi A, Suzuki Y, Ono S, Sato H, Sato Y. 1983. Effect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis. Infect. Immun. 41:1138-1143. (Pubitemid 13049293)
13. Kallonen T, He Q. 2009. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev. Vaccines 8:863-875.
14. Litt DJ, Neal SE, Fry NK. 2009. Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type. J. Clin. Microbiol. 47:680-688.
15. Lynn F, Reed GF, Meade BD. 1996. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin. Diagn. Lab. Immunol. 3:689-700. (Pubitemid 26388804)
16. Meade BD, et al. 1995. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96: 570-575.
17. Medical Research Council. 1956. Vaccination against whooping cough. Relation between protection in children and results of laboratory tests. Br. Med. J. 2:454-462.
18. Mooi FR, Avest A, van der Heide HG. 1990. Structure of the Bordetella pertussis gene coding for the serotype 3 fimbrial subunit. FEMS Microbiol. Lett. 54:327-331.
19. Packard ER, Parton R, Coote JG, Fry NK. 2004. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J. Med. Microbiol. 53:355-365. (Pubitemid 38586500)
20. Poolman JT, Hallander HO. 2007. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev. Vaccines 6:47-56. (Pubitemid 46232480)
21. Preston NW, Carter EJ. 1992. Serotype specificity of vaccine-induced immunity to pertussis. Commun. Dis. Rep. CDR Rev. 2:R155-R156.
22. Robinson A, Ashworth LA, Baskerville A, Irons LI. 1985. Protection against intranasal infection of mice with Bordetella pertussis. Dev. Biol. Stand. 61:165-172. (Pubitemid 16110294)
23. Robinson A, Gorringe AR, Funnell SG, Fernandez MM. 1989. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7:321-324. (Pubitemid 19215712)
24. Rodríguez ME, Hellwig SM, Pérez Vidakovics ML, Berbers GA, van de Winkel GJ. 2006. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol. Med. Microbiol. 46:39-47.
25. Storsaeter J, Hallander HO, Gustafsson L, Olin P. 1998. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916. (Pubitemid 28473934)
26. Tiru M, Askelöf P, Granström M, Hallander HO. 1997. Bordetella pertussis serotype of clinical isolates in Sweden during 1970-1995 and influence of vaccine efficacy studies. Dev. Biol. Stand. 89:239-245.
27. Tsang RS, et al. 2004. Polymorphisms of the fimbria fim3 gene of Bordetella pertussis strains isolated in Canada. J. Clin. Microbiol. 42:5364-5367. (Pubitemid 39506258)
28. Willems R, Paul A, van der Heide HG, Avest AR, Mooi FR. 1990. Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation. EMBO J. 9:2803-2809.
29. Willems R, et al. 1993. Isolation of a putative fimbrial adhesin from Bordetella pertussis and the identification of its gene. Mol. Microbiol. 9:623-634. (Pubitemid 23248773)
30. World Health Organization. 2010. Pertussis vaccines: WHO position paper. Wky. Epidemiol. Rec. 85:385-400.
31. Xing D, et al. 2009. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin. Vaccine Immunol. 16:303-311.
32. Xu Y, et al. 2009. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. BMC Microbiol. 9:274.